The alternatives
Injectco scores 68/100 (grade C, ranked #211) on The Verdict Score. Here are the top-rated GLP-1 providers we'd weigh against it — same six-factor rubric, and no score is adjusted for payment.
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
CoreAge Rx scores 94/100 to Injectco's 68, and our Injectco vs CoreAge Rx ruling sets the two out factor by factor.
HeliMeds offers compounded semaglutide and tirzepatide as well as brand-name Wegovy and Zepbound.
HeliMeds matches Injectco at 68/100; our HeliMeds ruling in full has the pricing conditions and the caveats in detail.
Knownwell is a weight-inclusive metabolic and primary care company co-founded by an obesity-medicine specialist.
Knownwell matches Injectco at 68/100; our Knownwell ruling in full has the pricing conditions and the caveats in detail.
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.
GoodRx matches Injectco at 68/100; our full write-up on GoodRx has the pricing conditions and the caveats in detail.
LevelsRx is a US direct-to-consumer telehealth offering compounded GLP-1 weight-loss medication, including compounded semaglutide (injectable and an oral liposomal liquid) starting at 150 dollars per month…
LevelsRx matches Injectco at 68/100; our LevelsRx ruling in full has the pricing conditions and the caveats in detail.
Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo).
Freya Meds matches Injectco at 68/100; the full Freya Meds review has the pricing conditions and the caveats in detail.
Telehealth weight loss provider offering compounded tirzepatide programs.
Livv matches Injectco at 68/100; the full Livv review has the pricing conditions and the caveats in detail.
See the complete rankings or head to the comparison hub.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Not medical advice; see our disclosure.